JAMA study puts nicotine patches on par with Pfizer's Chantix; NICE gives final OK to a slate of cancer meds;

@FiercePharma: India and France committed to restart trade talks stalled on GVK row. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: ICYMI: J&J's new launches deliver, but overall sales fall short on hep C, strong dollar. Article | Follow @CarlyHFierce

> Pfizer's ($PFE) stop-smoking drug Chantix failed to beat nicotine patches in a 12-week open-label study published Tuesday by the Journal of the American Medical Association. Report

> U.K. cost watchdogs have given a final thumbs-up to AstraZeneca's ($AZN) Lynparza, Bayer's Xofigo, Astellas' Xtandi and Novartis' ($NVS) Farydak. Report

> The U.K.'s National Institute of Health and Care Excellence (NICE) remains unconvinced that Eli Lilly's ($LLY) stomach cancer med Cyramza is worth its price. Report

> According to J&J ($JNJ) CEO Alex Gorsky, the healthcare industry's investment in patient support programs and other value-added services is still in the "early innings." Report

> The Turkish government put through price increases on thousands of drugs. Report

> Cost regulators in the U.K. have approved routine use of Boehringer Ingelheim's Ofev as a treatment for some patients with idopathic pulmonary fibrosis (IPF).

Medical Device News

@FierceMedDev: J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations. Story | Follow @FierceMedDev

@EmilyWFierce: Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings. ICYMI from FiercePharma | Follow @EmilyWFierce

> Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article

> Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. More

> Illumina finds match in Australian genomics company for transplant sequencing work. Report

Biotech News

@FierceBiotech: Researchers have isolated human monoclonal antibodies that target multiple strains of Ebola. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: $MNKD call on Feb. 3 gives investors a chance to ask a few questions. Release | Follow @JohnCFierce

> Langer-backed biotech reboots with $38M, new name and new cancer drug tech. More

> Novartis reshuffles its $9B R&D operation to save $1B a year. Report

> Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round. Article

Biotech Research News

> Researchers have isolated human monoclonal antibodies that target multiple strains of Ebola. Story

> Science team says they've taken another step toward a potential cure for diabetes. More

> UT Southwestern team says new liver cancer therapy shows promise in mice. Report

> New molecule targets cancer stem cells. Item

> UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. Article

Vaccines News

> Takeda's Hib vaccine gets Japanese approval. More

> Case Western, Merck team spotlights vaccine response predictors. Report

> U.K., Gates pledge $4.3 billion to take malaria fight beyond vax. Story

> U.K. committee warns the country is unprepared for an epidemic. Item

> Zika outbreak triggers R&D attention from pharma, governments. Article

Pharma Marketing News

> Time to tap YouTube for talent? Cold remedy Zicam goes there in deal with singer Tyler Ward. More

> New brands, stepped-up spending drive big TV-ad outlay for diabetes in 2015. Story

> What do docs want? Face-to-face tablet meetings with reps. More

> Massachusetts AG threatens legal action against Gilead over pricey hep C meds. Item

> Shire's back on track with its dry-eye threat to Allergan's Restasis. Article

And Finally... Counterfeit drugs are a growing problem in Los Angeles. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.